Editorial: The intricate innate immune-cancer cell relationship in the context of tumor angiogenesis, immunity and microbiota: The angiogenic switch in the tumor microenvironment as a key target for immunotherapies.
作者信息
Mortara Lorenzo, Benest Andrew V, Derosa Lisa, Chouaib Salem, Ribatti Domenico
机构信息
Laboratory of Immunology and General Pathology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Endothelial Quiescence Group, Centre for Cancer Sciences, Biodiscovery Institute, School of Medicine University of Nottingham, Nottingham, United Kingdom.
出版信息
Front Immunol. 2022 Oct 6;13:1045074. doi: 10.3389/fimmu.2022.1045074. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: The intricate innate immune-cancer cell relationship in the context of tumor angiogenesis, immunity and microbiota: The angiogenic switch in the tumor microenvironment as a key target for immunotherapies.
Front Immunol. 2022 Oct 6;13:1045074. doi: 10.3389/fimmu.2022.1045074. eCollection 2022.
2
Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.
Front Immunol. 2018 Apr 5;9:527. doi: 10.3389/fimmu.2018.00527. eCollection 2018.
3
Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Front Immunol. 2022 Nov 10;13:1035323. doi: 10.3389/fimmu.2022.1035323. eCollection 2022.
4
Regulation of innate immune system function by the microbiome: Consequences for tumor immunity and cancer immunotherapy.
Semin Immunol. 2023 Mar;66:101724. doi: 10.1016/j.smim.2023.101724. Epub 2023 Feb 7.
5
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
Exp Mol Med. 2020 Sep;52(9):1475-1485. doi: 10.1038/s12276-020-00500-y. Epub 2020 Sep 11.
6
[Vascular normalization and cancer immunotherapy].
Zhongguo Fei Ai Za Zhi. 2014 Mar;17(3):273-6. doi: 10.3779/j.issn.1009-3419.2014.03.16.
7
Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers.
Front Immunol. 2024 Dec 3;15:1487610. doi: 10.3389/fimmu.2024.1487610. eCollection 2024.
8
Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.
Nat Immunol. 2022 Sep;23(9):1309-1316. doi: 10.1038/s41590-022-01291-2. Epub 2022 Aug 24.
9
Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality.
Trends Mol Med. 2023 Nov;29(11):897-911. doi: 10.1016/j.molmed.2023.08.004. Epub 2023 Sep 11.
10
Innate Immunity in Cancer Biology and Therapy.
Int J Mol Sci. 2023 Jul 8;24(14):11233. doi: 10.3390/ijms241411233.
引用本文的文献
1
Epithelial and macrophage cell interaction in cervical cancer through single-cell RNA-sequencing and spatial analysis.
Front Immunol. 2025 Apr 9;16:1537785. doi: 10.3389/fimmu.2025.1537785. eCollection 2025.
2
Tumor microenvironment as a complex milieu driving cancer progression: a mini review.
Clin Transl Oncol. 2025 May;27(5):1943-1952. doi: 10.1007/s12094-024-03697-w. Epub 2024 Sep 28.
3
Identification of a new gene signature for prognostic evaluation in cervical cancer: based on cuproptosis-associated angiogenesis and multi-omics analysis.
Cancer Cell Int. 2024 Jan 10;24(1):23. doi: 10.1186/s12935-023-03189-x.
Zotero 插件